Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 292

1.

The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment.

De Marchi E, Orioli E, Pegoraro A, Sangaletti S, Portararo P, Curti A, Colombo MP, Di Virgilio F, Adinolfi E.

Oncogene. 2019 Jan 17. doi: 10.1038/s41388-019-0684-y. [Epub ahead of print]

PMID:
30655604
2.

Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.

Vernieri C, Signorelli D, Galli G, Ganzinelli M, Moro M, Fabbri A, Tamborini E, Marabese M, Caiola E, Broggini M, Hollander L, Gallucci R, Vandoni G, Gavazzi C, Triulzi T, Colombo MP, Rizzo AM, Corsetto PA, Pruneri G, de Braud F, Sozzi G, Torri V, Garassino MC.

Clin Lung Cancer. 2018 Dec 19. pii: S1525-7304(18)30335-8. doi: 10.1016/j.cllc.2018.12.011. [Epub ahead of print]

PMID:
30617039
3.

Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity.

Garassino MC, Torri V, Colombo MP, Sica A.

Cancer Res. 2018 Oct 15;78(20):5729-5730. doi: 10.1158/0008-5472.CAN-18-2245.

PMID:
30322956
4.

Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer.

Andriani F, Landoni E, Mensah M, Facchinetti F, Miceli R, Tagliabue E, Giussani M, Callari M, De Cecco L, Colombo MP, Roz L, Pastorino U, Sozzi G.

BMC Cancer. 2018 Sep 18;18(1):899. doi: 10.1186/s12885-018-4772-0.

5.

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis.

Nanni P, De Giovanni C, Burocchi A, Nicoletti G, Landuzzi L, Palladini A, Ianzano ML, Arioli I, Colombo MP, Lollini PL.

Oncoimmunology. 2018 Jun 11;7(8):e1465164. doi: 10.1080/2162402X.2018.1465164. eCollection 2018.

6.

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC.

Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.

PMID:
30206165
7.

Is GPNMB the Achilles' Heel of Mo-MDSC While Marking Their Suppressive Activity?

Colombo MP.

Clin Cancer Res. 2019 Jan 15;25(2):453-454. doi: 10.1158/1078-0432.CCR-18-2334. Epub 2018 Aug 30.

PMID:
30166442
8.

cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells.

Majorini MT, Manenti G, Mano M, De Cecco L, Conti A, Pinciroli P, Fontanella E, Tagliabue E, Chiodoni C, Colombo MP, Delia D, Lecis D.

Cell Death Differ. 2018 Dec;25(12):2147-2164. doi: 10.1038/s41418-018-0100-0. Epub 2018 Apr 19.

9.

Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer.

Jachetti E, Cancila V, Rigoni A, Bongiovanni L, Cappetti B, Belmonte B, Enriquez C, Casalini P, Ostano P, Frossi B, Sangaletti S, Chiodoni C, Chiorino G, Pucillo CE, Tripodo C, Colombo MP.

Cancer Immunol Res. 2018 May;6(5):552-565. doi: 10.1158/2326-6066.CIR-17-0385. Epub 2018 Mar 9.

PMID:
29523597
10.

Mast cells, basophils and eosinophils: From allergy to cancer.

Rigoni A, Colombo MP, Pucillo C.

Semin Immunol. 2018 Feb;35:29-34. doi: 10.1016/j.smim.2018.02.001. Epub 2018 Feb 7. Review.

PMID:
29428698
11.

ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells.

Lecciso M, Ocadlikova D, Sangaletti S, Trabanelli S, De Marchi E, Orioli E, Pegoraro A, Portararo P, Jandus C, Bontadini A, Redavid A, Salvestrini V, Romero P, Colombo MP, Di Virgilio F, Cavo M, Adinolfi E, Curti A.

Front Immunol. 2017 Dec 22;8:1918. doi: 10.3389/fimmu.2017.01918. eCollection 2017.

12.

Separation of Dual Oxidase 2 and Lactoperoxidase Expression in Intestinal Crypts and Species Differences May Limit Hydrogen Peroxide Scavenging During Mucosal Healing in Mice and Humans.

Rigoni A, Poulsom R, Jeffery R, Mehta S, Lewis A, Yau C, Giannoulatou E, Feakins R, Lindsay JO, Colombo MP, Silver A.

Inflamm Bowel Dis. 2017 Dec 19;24(1):136-148. doi: 10.1093/ibd/izx024.

PMID:
29272487
13.

On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?

Colombo MP.

Clin Cancer Res. 2017 Oct 15;23(20):5999-6001. doi: 10.1158/1078-0432.CCR-17-2332.

14.

Innovative Therapy, Monoclonal Antibodies and Beyond.

Di Nicola M, Apetoh L, Bellone M, Colombo MP, Dotti G, Ferrone S, Muscolini M, Hiscott J, Anichini A, Pupa SM, Braud F, Del Vecchio M.

Cytokine Growth Factor Rev. 2017 Dec;38:1-9. doi: 10.1016/j.cytogfr.2017.10.002. Epub 2017 Oct 5.

PMID:
29029813
15.

Reciprocal influence of B cells and tumor macro and microenvironments in the ApcMin/+ model of colorectal cancer.

Mion F, Vetrano S, Tonon S, Valeri V, Piontini A, Burocchi A, Petti L, Frossi B, Gulino A, Tripodo C, Colombo MP, Pucillo CE.

Oncoimmunology. 2017 Jun 19;6(8):e1336593. doi: 10.1080/2162402X.2017.1336593. eCollection 2017.

16.

Antibody-mediated blockade of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities.

Miotti S, Gulino A, Ferri R, Parenza M, Chronowska A, Lecis D, Sangaletti S, Tagliabue E, Tripodo C, Colombo MP.

FASEB J. 2017 Dec;31(12):5356-5370. doi: 10.1096/fj.201700377R. Epub 2017 Aug 8.

PMID:
28790175
17.

The good and bad of targeting cancer-associated extracellular matrix.

Sangaletti S, Chiodoni C, Tripodo C, Colombo MP.

Curr Opin Pharmacol. 2017 Aug;35:75-82. doi: 10.1016/j.coph.2017.06.003. Epub 2017 Jul 19. Review.

PMID:
28734136
18.

Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT).

Russo V, Amadori A, Bregni M, Calabrò L, Colombo MP, Di Nicola M, Ferrucci PF, Proietti E, Maio M, Bellone M.

Cytokine Growth Factor Rev. 2017 Aug;36:1-3. doi: 10.1016/j.cytogfr.2017.06.004. Epub 2017 Jun 16.

PMID:
28634022
19.

Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.

Ratti C, Botti L, Cancila V, Galvan S, Torselli I, Garofalo C, Manara MC, Bongiovanni L, Valenti CF, Burocchi A, Parenza M, Cappetti B, Sangaletti S, Tripodo C, Scotlandi K, Colombo MP, Chiodoni C.

Clin Cancer Res. 2017 Sep 1;23(17):5149-5161. doi: 10.1158/1078-0432.CCR-16-3186. Epub 2017 Jun 9.

20.

Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling.

Tripodo C, Burocchi A, Piccaluga PP, Chiodoni C, Portararo P, Cappetti B, Botti L, Gulino A, Isidori A, Liso A, Visani G, Martelli MP, Falini B, Pandolfi PP, Colombo MP, Sangaletti S.

Cancer Res. 2017 Jul 1;77(13):3685-3699. doi: 10.1158/0008-5472.CAN-17-1098. Epub 2017 May 23.

21.

Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments.

Sangaletti S, Chiodoni C, Tripodo C, Colombo MP.

Cancer Immunol Immunother. 2017 Aug;66(8):1059-1067. doi: 10.1007/s00262-017-2014-y. Epub 2017 May 13. Review.

PMID:
28501940
22.

Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8+ T-cell Recognition of a Retroviral Antigen.

Probst P, Kopp J, Oxenius A, Colombo MP, Ritz D, Fugmann T, Neri D.

Cancer Res. 2017 Jul 1;77(13):3644-3654. doi: 10.1158/0008-5472.CAN-16-2946. Epub 2017 May 8.

23.

Rheostatic Functions of Mast Cells in the Control of Innate and Adaptive Immune Responses.

Frossi B, Mion F, Tripodo C, Colombo MP, Pucillo CE.

Trends Immunol. 2017 Sep;38(9):648-656. doi: 10.1016/j.it.2017.04.001. Epub 2017 Apr 25. Review.

PMID:
28462845
24.

Matricellular proteins tune myeloid-derived suppressor cell recruitment and function in breast cancer.

Chiodoni C, Sangaletti S, Colombo MP.

J Leukoc Biol. 2017 Aug;102(2):287-292. doi: 10.1189/jlb.3MR1016-447R. Epub 2017 Feb 1. Review.

PMID:
28148719
25.

Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-β.

Jachetti E, Rigoni A, Bongiovanni L, Arioli I, Botti L, Parenza M, Cancila V, Chiodoni C, Festinese F, Bellone M, Tardanico R, Tripodo C, Colombo MP.

Mol Cancer Ther. 2017 Feb;16(2):365-375. doi: 10.1158/1535-7163.MCT-16-0466. Epub 2016 Dec 15.

26.

CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling.

Manara MC, Terracciano M, Mancarella C, Sciandra M, Guerzoni C, Pasello M, Grilli A, Zini N, Picci P, Colombo MP, Morrione A, Scotlandi K.

Oncotarget. 2016 Nov 29;7(48):79925-79942. doi: 10.18632/oncotarget.13160.

27.

Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity.

Sangaletti S, Tripodo C, Santangelo A, Castioni N, Portararo P, Gulino A, Botti L, Parenza M, Cappetti B, Orlandi R, Tagliabue E, Chiodoni C, Colombo MP.

Cell Rep. 2016 Sep 27;17(1):233-248. doi: 10.1016/j.celrep.2016.08.075.

28.

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.

Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI.

Nat Commun. 2016 Jul 6;7:12150. doi: 10.1038/ncomms12150. Review.

29.

Healthy and tumoral tissue resistivity in wild-type and sparc-/- animal models.

Meroni D, Mauri G, Bovio D, Bianchi AM, Chiodoni C, Colombo MP, Meroni E, Aliverti A.

Med Biol Eng Comput. 2016 Dec;54(12):1949-1957. Epub 2016 Apr 21.

PMID:
27099155
30.

TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Armed Exosomes Deliver Proapoptotic Signals to Tumor Site.

Rivoltini L, Chiodoni C, Squarcina P, Tortoreto M, Villa A, Vergani B, Bürdek M, Botti L, Arioli I, Cova A, Mauri G, Vergani E, Bianchi B, Della Mina P, Cantone L, Bollati V, Zaffaroni N, Gianni AM, Colombo MP, Huber V.

Clin Cancer Res. 2016 Jul 15;22(14):3499-512. doi: 10.1158/1078-0432.CCR-15-2170. Epub 2016 Mar 4.

31.

MEF2C and SOCS2 in stemness regulation.

Vitali C, Tripodo C, Colombo MP.

Oncoscience. 2015 Dec 28;2(12):936-7. eCollection 2015. No abstract available.

32.

Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.

Mauri G, Jachetti E, Comuzzi B, Dugo M, Arioli I, Miotti S, Sangaletti S, Di Carlo E, Tripodo C, Colombo MP.

Oncotarget. 2016 Jan 26;7(4):3905-20. doi: 10.18632/oncotarget.6678.

33.

CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-κB signaling.

Ventura S, Aryee DN, Felicetti F, De Feo A, Mancarella C, Manara MC, Picci P, Colombo MP, Kovar H, Carè A, Scotlandi K.

Oncogene. 2016 Jul 28;35(30):3944-54. doi: 10.1038/onc.2015.463. Epub 2015 Nov 30.

34.

RORC1 Regulates Tumor-Promoting "Emergency" Granulo-Monocytopoiesis.

Strauss L, Sangaletti S, Consonni FM, Szebeni G, Morlacchi S, Totaro MG, Porta C, Anselmo A, Tartari S, Doni A, Zitelli F, Tripodo C, Colombo MP, Sica A.

Cancer Cell. 2015 Aug 10;28(2):253-69. doi: 10.1016/j.ccell.2015.07.006.

35.

Mast Cells Infiltrating Inflamed or Transformed Gut Alternatively Sustain Mucosal Healing or Tumor Growth.

Rigoni A, Bongiovanni L, Burocchi A, Sangaletti S, Danelli L, Guarnotta C, Lewis A, Rizzo A, Silver AR, Tripodo C, Colombo MP.

Cancer Res. 2015 Sep 15;75(18):3760-70. doi: 10.1158/0008-5472.CAN-14-3767. Epub 2015 Jul 23.

36.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

37.

The ins and outs of osteopontin.

Chiodoni C, Sangaletti S, Tripodo C, Colombo MP.

Oncoimmunology. 2015 Apr 2;4(3):e978711. eCollection 2015 Mar.

38.

Regulated Expression of miR-155 is Required for iNKT Cell Development.

Burocchi A, Pittoni P, Tili E, Rigoni A, Costinean S, Croce CM, Colombo MP.

Front Immunol. 2015 Mar 30;6:140. doi: 10.3389/fimmu.2015.00140. eCollection 2015.

39.

SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias.

Vitali C, Bassani C, Chiodoni C, Fellini E, Guarnotta C, Miotti S, Sangaletti S, Fuligni F, De Cecco L, Piccaluga PP, Colombo MP, Tripodo C.

Cancer Res. 2015 Jun 1;75(11):2387-99. doi: 10.1158/0008-5472.CAN-14-3625. Epub 2015 Apr 9.

40.

SCD5-induced oleic acid production reduces melanoma malignancy by intracellular retention of SPARC and cathepsin B.

Bellenghi M, Puglisi R, Pedini F, De Feo A, Felicetti F, Bottero L, Sangaletti S, Errico MC, Petrini M, Gesumundo C, Denaro M, Felli N, Pasquini L, Tripodo C, Colombo MP, Carè A, Mattia G.

J Pathol. 2015 Jul;236(3):315-25. doi: 10.1002/path.4535. Epub 2015 Apr 20.

PMID:
25802234
41.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

42.

CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin.

Guerzoni C, Fiori V, Terracciano M, Manara MC, Moricoli D, Pasello M, Sciandra M, Nicoletti G, Gellini M, Dominici S, Chiodoni C, Fornasari PM, Lollini PL, Colombo MP, Picci P, Cianfriglia M, Magnani M, Scotlandi K.

Clin Cancer Res. 2015 Jan 1;21(1):146-56. doi: 10.1158/1078-0432.CCR-14-0492. Epub 2014 Dec 11.

43.

Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity.

Ferrari-Amorotti G, Chiodoni C, Shen F, Cattelani S, Soliera AR, Manzotti G, Grisendi G, Dominici M, Rivasi F, Colombo MP, Fatatis A, Calabretta B.

Neoplasia. 2014 Dec;16(12):1047-58. doi: 10.1016/j.neo.2014.10.006.

44.

Mast cells boost myeloid-derived suppressor cell activity and contribute to the development of tumor-favoring microenvironment.

Danelli L, Frossi B, Gri G, Mion F, Guarnotta C, Bongiovanni L, Tripodo C, Mariuzzi L, Marzinotto S, Rigoni A, Blank U, Colombo MP, Pucillo CE.

Cancer Immunol Res. 2015 Jan;3(1):85-95. doi: 10.1158/2326-6066.CIR-14-0102. Epub 2014 Oct 28.

45.

Mast cells control the expansion and differentiation of IL-10-competent B cells.

Mion F, D'Incà F, Danelli L, Toffoletto B, Guarnotta C, Frossi B, Burocchi A, Rigoni A, Gerdes N, Lutgens E, Tripodo C, Colombo MP, Rivera J, Vitale G, Pucillo CE.

J Immunol. 2014 Nov 1;193(9):4568-79. doi: 10.4049/jimmunol.1302593. Epub 2014 Sep 29.

46.

The Role of Mast Cells in Molding the Tumor Microenvironment.

Rigoni A, Colombo MP, Pucillo C.

Cancer Microenviron. 2015 Dec;8(3):167-76. doi: 10.1007/s12307-014-0152-8. Epub 2014 Sep 7.

47.

Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies.

Sangaletti S, Tripodo C, Portararo P, Dugo M, Vitali C, Botti L, Guarnotta C, Cappetti B, Gulino A, Torselli I, Casalini P, Chiodoni C, Colombo MP.

Oncoimmunology. 2014 Jun 5;3:e28989. eCollection 2014.

48.

Osteopontin shapes immunosuppression in the metastatic niche.

Sangaletti S, Tripodo C, Sandri S, Torselli I, Vitali C, Ratti C, Botti L, Burocchi A, Porcasi R, Tomirotti A, Colombo MP, Chiodoni C.

Cancer Res. 2014 Sep 1;74(17):4706-19. doi: 10.1158/0008-5472.CAN-13-3334. Epub 2014 Jul 17.

49.

CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2.

Sciandra M, Marino MT, Manara MC, Guerzoni C, Grano M, Oranger A, Lucarelli E, Lollini PL, Dozza B, Pratelli L, Renzo MF, Colombo MP, Picci P, Scotlandi K.

J Bone Miner Res. 2014;29(5):1295-309. doi: 10.1002/jbmr.2141.

50.

Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma.

Franco G, Guarnotta C, Frossi B, Piccaluga PP, Boveri E, Gulino A, Fuligni F, Rigoni A, Porcasi R, Buffa S, Betto E, Florena AM, Franco V, Iannitto E, Arcaini L, Pileri SA, Pucillo C, Colombo MP, Sangaletti S, Tripodo C.

Blood. 2014 Mar 20;123(12):1836-49. doi: 10.1182/blood-2013-04-497271. Epub 2014 Jan 22.

Supplemental Content

Loading ...
Support Center